DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Epix Pharmaceuticals
Epix Pharmaceuticals
178S ASMS Directory of Members DAVID AASERUD the Lubrizol
Oral Presentation Disclosures
Beyond Borders Global Biotechnology Report 2009 “It Is Different This Time Because This Crisis Is Deep-Rooted, Systemic and Persistent
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder
Health Care Equity Capital Markets Review
Disclosures ASCP Annual Meeting FAIRMONT SCOTTSDALE PRINCESS MAY 30-JUNE 3, 2016
Office of Sponsored Rseearch Annual Report
Poster Session II the Effects of Targeted NMDA Receptor Interventions on Sociability December 7, 2010 5:30PM-7:30 PM in a Standardized Paradigm
C:\Myfiles\Website\Dph Rcp WIP
ELS-Tíðindi Apríl 2009
[ Emc-Lusinnufll'lergcrta'rgets
Scripps Florida 2008
Discovery on Target Diverse Pathways Multiple Targets One Event
2020 December
Clinical Neuroscience Solutions, Inc
Return of Private Foundation OMB No 15450052 F
Blind, Placebo-Controlled Study of NSI-189 Phosphate, a Neurogenic
United States Securities and Exchange Commission Form
Top View
2017 Ada Annual Meeting
Stage New Drug Discovery
6. Initial Effects of the Economic Crisis Annexes: A1 - Background Information A2 - Methodological Notes A3 - List of EU1000 and Non-EU1000 Companies
FY08 Flat File
Neuroscience Education Institute Full-Disclosure Form Title/Affiliation
Efficacy of Intravenous Ketamine Treatment in Anxious Versus Nonanxious Unipolar Treatment-Resistant Depression
EPIX . January 2008
Preliminary Program Last Updated on Monday, July 7, 2008 02:00:01 EDT
ISPE Boston News
Epix Pharmaceuticalsinc
Senior Staff Biographies
Possible Mechanisms and Clinical Implications
New Pharmacological Treatments for Resistant Depression
DFA INVESTMENT TRUST CO (Form: N-Q, Filing Date: 04/29/2005)
GSK Annual Report & Accounts 2006
ASCP 2018 ANNUAL MEETING: Treatment of Psychiatric Illness Across the Lifespan
Treatment Resistant Depression
Real World Drug Discovery : a Chemist's Guide to Biotech And
EPIX Pharmaceuticals, Inc. Fundamental
Disclosures (Lifetime): Maurizio Fava, MD Updated: April 2021
Early Stage & Preclinical MOA Counts Early Stage & Preclinical Company
Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No
ALGUNOS APUNTES SOBRE EL FUTURO CERCANO Pág
Explanation of Conflict of Interest Disclosure Parts: Part One: All Financial Involvement with a Pharmaceutical Or Biotechnology
Disclosures (Lifetime): Maurizio Fava, MD (Updated: October 2020)
Poster Session I
ISPE Boston News
PDF the 2009 EU Industrial R&D Investment Scoreboard
Securities Listed on the Nasdaq Stock Market As of August 9, 2005
Table of Contents
List of 13F Securities, Second Quarter 2006